Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
Top Cited Papers
- 13 October 2015
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (20) , 4790-4805
Abstract
Background and Purpose: Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors.Experimental Approach: Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdhQ7/Q7 cell model of striatal neurons endogenously expressing CB1 receptors. Cells were treated with 2‐arachidonylglycerol or Δ9‐tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol.Key Results: Cannabidiol reduced the efficacy and potency of 2‐arachidonylglycerol and Δ9‐tetrahydrocannabinol on PLCβ3‐ and ERK1/2‐dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdhQ7/Q7) expressing CB1 receptors. By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor.Conclusions and Implications: Cannabidiol behaved as a non‐competitive negative allosteric modulator of CB1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.Keywords
Funding Information
- Canadian Institutes of Health Research (ROP-97185)
- Canadian Institutes of Health Research (MOP-97768)
- Killam Trusts
- Nova Scotia Health Research Foundation
- King Abdulaziz University of Saudi Arabia
- Huntington Society of Canada
This publication has 47 references indexed in Scilit:
- Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewBritish Journal of Pharmacology, 2015
- Type 1 Cannabinoid Receptor Ligands Display Functional Selectivity in a Cell Culture Model of Striatal Medium Spiny Projection NeuronsJournal of Biological Chemistry, 2014
- Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor LigandsMolecular Pharmacology, 2014
- The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patientsJournal of Neuroimmunology, 2014
- Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 ReceptorJournal of Medicinal Chemistry, 2012
- Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase ActivationJournal of Biological Chemistry, 2012
- Allosteric modulation of G protein-coupled receptors: A pharmacological perspectiveNeuropharmacology, 2011
- Physical and functional interaction between CB1cannabinoid receptors and β2‐adrenoceptorsBritish Journal of Pharmacology, 2010
- The Cannabinoid 1–Receptor Silent Antagonist O-2050 Attenuates Preference for High-Fat Diet and Activated Astrocytes in MiceJournal of Pharmacological Sciences, 2010
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007